On February 10, 2026 Ferronova reported it has completed enrolment of patients for its two-year trial to progress commercialisation of FerroTrace, a novel nanoparticle image-guided surgery solution for hard-to-treat cancers.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The technology is intended to assist surgeons in identifying lymph nodes involved in metastatic spread, thereby enabling targeted removal and reducing the risk of post-surgical recurrence. The study is the first of its kind in which tracer injection to map lymphatic drainage pathways is performed prior to any chemotherapy or radiotherapy.

Key highlights

Patient enrolment has been completed in adults with gastric and oesophageal cancers across five hospital sites in Australia, with a total of 62 patients enrolled, exceeding initial projections.
Evaluations and results from the trial are expected to be available in July 2026.
The trial follows several smaller first-in-human studies conducted between 2020-2024.
FerroTrace addresses an unmet need in surgical guidance for hard-to-treat cancers, with oesophageal and stomach cancers in the world’s top five deadliest cancer types.
Stomach and oesophageal cancers affect more than 1.8 million people worldwide each year, with recurrence after surgery occuring in up to 60% of patients. In Australia, three-year survival for oseophageal cancer remains at just 27%.
FerroTrace uses super-paramagnetic iron oxide nanoparticles that bind to cells within lymph nodes. The technology is designed to support more precise surgery, helping surgeons to identify and remove cancer-affected lymph nodes that are frequently missed during standard procedures.

Stewart Bartlett Chief Executive Officer of Ferronova said he was delighted that the trial had completed recruitment.

"The investigators at the Royal Adelaide, Queen Elizabeth, Flinders, Austin Hospital, and Peter MacCallum Cancer Centre have done an amazing job recruiting patients in a relatively short time. We are looking forward to working with them to complete the final follow-up visits and analyse the data."

"We hope to give surgeons the opportunity to work with greater diagnostic accuracy and precision, enabling less invasive surgery in some patients, and more precise surgery overall, ensuring all cancer-affected lymph nodes are identified and removed. This trial is an important step in validating our technology as we move towards commercial availability."

Appointment of new advisory board member
Ferronova has also appointed a new scientific advisory board member with Ms Aki Smith, a patient advocate, taking up the role this month. Ms Smith founded the US-based charity ‘Hope for Stomach Cancer’ following her father’s diagnosis. The charity provides resources and support to those living with stomach cancer and their families.

Mr Bartlett welcomed Ms Smith to the advisory board, saying her lived experience will help to inform future trial design and innovations.

"The role of Ms Smith and other members for the scientific advisory board is very important to our company. Ferronova is deeply committed to finding new solutions for those affected by these aggressive and difficult to treat cancers.

"We are very supportive of patients having a greater voice in the development and evaluation of new treatments, including those involving our technology."

(Press release, Ferronova, FEB 9, 2026, View Source [SID1234662578])

On February 10, 2026 Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company leveraging artificial intelligence to accelerate oncology drug discovery and development, reported that CEO and President Panna Sharma will present at the 7th Glioblastoma Drug Development Summit, February 17–19, 2026, in Boston, MA.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

More information about the summit is available at: https://glioblastoma-drugdevelopment.com.

Lantern’s proprietary AI and machine learning platform, RADR, powered the development of LP-184 / STAR-001, a novel brain-penetrant therapeutic candidate. This work has driven the creation of Lantern’s wholly owned subsidiary, Starlight Therapeutics, which is advancing clinical development for multiple CNS cancers, including recurrent glioblastoma and pediatric brain tumors such as atypical teratoid/rhabdoid tumors (ATRT)—for which STAR-001 has received both FDA Orphan Drug Designation and Rare Pediatric Disease Designation.

In his presentation on Day Two (Thursday, February 19, 2026, at 10:30 a.m. ET), Mr. Sharma will highlight how Lantern applied RADR to:

Elucidate the mechanism of action of STAR-001
Identify patient biomarkers to inform clinical use
Select optimal cancer indications
Discover novel combination therapies in neuro-oncology
The talk will emphasize AI-driven insights and approaches that are helping overcome challenges in treating aggressive brain cancers like glioblastoma and ATRT.

(Press release, Lantern Pharma, FEB 10, 2026, View Source [SID1234662576])

On February 10, 2026 Oncotelic Therapeutics, Inc. (OTCQB: OTLC) ("Oncotelic" or the "Company"), a clinical-stage biopharmaceutical company focused on oncology, immunotherapy, and CNS-related diseases, reported an update on key development progress achieved during 2025 and outlined its strategic direction as the Company enters 2026 with continued momentum across its pipeline.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

2025: Continued Execution Across a Late-Stage, Diversified Pipeline

Oncotelic transitioned from platform build-out to execution and validation, advancing AI-driven discovery (PDAOAI), moving key assets into the clinic, publishing high-impact translational science, and reinforcing asset value through independent validation. Collectively, these milestones establish a strong foundation for late-stage development, partnering, and strategic financing.

Oncotelic Therapeutics – 2025 Key Accomplishments

1. Platform Innovation & AI Enablement (PDAOAI)

In 2025, Oncotelic formally unveiled PDAOAI, its proprietary AI-enabled knowledge platform built on a comprehensive TGF-β-centric corpus. The platform was expanded to support interactive querying, biomarker discovery, and translational hypothesis generation, and was publicly introduced alongside peer-reviewed GBM and pancreatic cancer research. PDAOAI now functions as a cross-program decision-support layer integrating molecular biology, clinical outcomes, and regulatory-grade literature.

2. Clinical Progress & First-in-Human Readiness

Oncotelic achieved multiple clinical milestones across its pipeline. The company successfully completed a Phase 1 clinical trial of OT-101 in combination with IL-2. In parallel, its IV everolimus Deciparticle program (Sapu-003) advanced from preclinical development into first-in-human clinical testing.

3. Deciparticle Platform Validation (Sapu-003)

Throughout 2025, Oncotelic released a coordinated body of data validating the Deciparticle platform:

Demonstrated broad applicability across hydrophobic small-molecule drug classes
Reported favorable PK and tissue-distribution profiles, including reduced gastrointestinal accumulation compared with oral everolimus
Introduced a biomarker-guided framework to identify patient populations most likely to benefit from IV mTOR inhibition
These results position Deciparticle as a differentiated delivery technology for oncology and other systemic indications.

4. Peer-Reviewed Science & Biomarker Leadership

Oncotelic and collaborators published multiple peer-reviewed studies in 2025, reinforcing the company’s leadership in TGFB2-centric biology. Key publications linked TGFB2 expression and methylation status to survival outcomes in pancreatic cancer, glioblastoma, and liver cancer, including age- and context-dependent effects. Additional work reviewed sub-20 nm nanoparticle design principles, supporting the scientific rationale behind the Deciparticle platform.

5. Strategic Partnerships & Global Development Infrastructure

The company entered a strategic partnership with Medicilon to access rapid IND-enabling capabilities. These capabilities complement Oncotelic’s global regulatory strategy.

6. Corporate Development, Valuation & Visibility

In 2025, an independent third-party analysis valued the GMP Bio joint-venture pipeline at approximately $1.7 billion, materially strengthening Oncotelic’s asset-level valuation narrative. The company increased capital-markets visibility through various investor presentations, while continuing disciplined communication around pipeline maturation and platform leverage.

Looking Ahead to 2026: Sustained Momentum, Strategic Execution, and Value Recognition

As the Company enters 2026, Oncotelic plans to build on the progress achieved in 2025 with an emphasis on continued development momentum, thoughtful capital allocation, strategic execution, and increased financial transparency. The Company’s forward priorities include:

Advancing clinical programs toward their next inflection points
Further evaluating regulatory and development pathways across oncology and CNS indications
Exploring partnership, licensing, and collaboration opportunities aligned with its late-stage assets
Continuing to strengthen operational readiness to support future growth initiatives
Completing a second independent U.S.-based valuation to support the remeasurement of its 45% equity interest in the GMP Bio joint venture, with the resulting valuation expected to be reflected on the Company’s balance sheet upon completion, subject to applicable accounting standards

Oncotelic believes its steady progress in 2025 has positioned the Company with a clear development trajectory, enhanced asset visibility, and multiple opportunities to unlock long-term value.

(Press release, Oncotelic, FEB 10, 2026, View Source [SID1234662575])

On February 10, 2026 Sutro Biopharma, Inc. (Sutro or the Company) (Nasdaq: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), reported the pricing of an underwritten offering of 7,868,383 shares of its common stock at a price of $13.98 per share. The gross proceeds from this offering are expected to be approximately $110.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by Sutro. All of the shares of common stock are being offered by Sutro. The offering is expected to close on or about February 11, 2026, subject to the satisfaction of customary closing conditions.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The offering includes participation from new and existing investors, including BVF Partners L.P., Samsara BioCapital, Coastlands Capital, Eventide Asset Management, Perceptive Advisors, RA Capital Management, ADAR1 Capital Management, Affinity Asset Advisors and Acuta Capital Partners.

Leerink Partners, TD Cowen and LifeSci Capital are acting as joint bookrunning managers for the proposed offering.

Sutro intends to use the net proceeds of this offering, together with its existing cash, cash equivalents and marketable securities, primarily for general corporate purposes, which may include funding research, clinical and process development and manufacturing of its product candidates, increasing its working capital, acquisitions or investments in businesses, products or technologies that are complementary to the Company, capital expenditures and other general corporate purposes.

The securities are being offered by Sutro pursuant to a registration statement on Form S-3 previously filed and declared effective by the Securities and Exchange Commission (SEC). A prospectus supplement and accompanying prospectus relating to this offering will be filed with the SEC. Copies of the prospectus supplement and the accompanying prospectus relating to this offering, may also be obtained, when available, from: Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, by telephone at (800) 808-7525, ext. 6105, or by email at [email protected]; TD Securities (USA) LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at [email protected]; or LifeSci Capital LLC, 1700 Broadway, 40th Floor, New York, NY 10019, or by email at [email protected] Electronic copies of the prospectus supplement and accompanying prospectus will also be available on the website of the SEC at View Source

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities of Sutro, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

(Press release, Sutro Biopharma, FEB 10, 2026, View Source [SID1234662574])

On February 10, 2026 Sanofi reported that it has completed the acquisition of Dynavax Technologies Corporation (Dynavax). The acquisition includes Dynavax’s adult hepatitis B vaccine HEPLISAV-B, which is currently marketed in the US and is differentiated by its two-dose regimen over one month. It also includes Dynavax’s shingles vaccine candidate (Z-1018), which is currently in phase 1/2 studies, and additional vaccine pipeline projects.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This acquisition augments Sanofi’s presence in adult immunization by bringing together Dynavax’s vaccines with Sanofi’s commercial reach, global scale, and development capabilities.

The tender offer for all outstanding shares of Dynavax common stock, par value $0.001 per share expired one minute after 11:59 P.M. EST, on February 9, 2026. The minimum condition and all the other conditions to the offer have been satisfied, and on February 10, 2026, Sanofi accepted for payment and will promptly pay for all shares validly tendered and not validly withdrawn.

Following its acceptance of the tendered shares, Sanofi completed its acquisition of Dynavax through the merger of a wholly owned subsidiary of Sanofi with and into Dynavax, pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with Dynavax continuing as the surviving corporation and becoming an indirect, wholly owned subsidiary of Sanofi. In connection with the merger, all Dynavax shares not validly tendered in the tender offer have been converted into the right to receive the same $15.50 per share in cash, without interest, subject to any applicable withholding taxes, that would have been paid had such shares been validly tendered in the tender offer. As of February 10, 2026, Dynavax common stock will cease to be traded on the NASDAQ Global Select Stock Market.

(Press release, Sanofi, FEB 10, 2026, View Source [SID1234662573])